Veterinary researcher collaborates aerosol-based treatment lung cancer

Veterinary researcher collaborates on aerosol-based treatment for lung cancer

11:48 AM, 25th April 2017
Veterinary researcher collaborates on aerosol-based treatment for lung cancer
Kansas State University's Masaaki Tamura, associate professor of anatomy and physiology, is collaborating with a Lawrence pharmaceutical firm on National Institutes of Health-funded research project.

Lung cancer patients may one day be able to breathe a sigh of relief because of a new potential treatment for the disease. Kansas State University's Masaaki Tamura is collaborating on a National Institutes of Health-funded research project for a therapeutic compound that would be administered directly to the lungs in aerosol form.

"The standard treatments for lung cancer include chemotherapy, radiation and surgery," said Tamura, who is an associate professor of anatomy and physiology in the College of Veterinary Medicine and affiliate of the university's Johnson Cancer Research Centre. "Cisplatin is the first-line chemotherapy for lung cancer, but intravenous delivery can be complicated by a variety of factors such as toxicities, poor penetration into tumours and lymph nodes, organ damage, and spontaneous drug resistance. Cancer becomes poorly responsive to chemotherapeutics after repetitive uses."

Chad Groer, chief science officer with Hylapharm in Lawrence, is the principal investigator on the project, which has received a $150,000 business development grant from the NIH. Hylapharm develops chemical-based therapeutics to treat cancer and partners with universities to test delivery methods and effectiveness of potential treatments and methods.

"We call this product HylaPlat," Groer said. "It delivers high-dose targeted cisplatin directly to the lungs to target primary lung cancers and lymphatic metastases. This would replace intravenous cisplatin therapy for advanced CD44-plus non-small cell lung cancers."

Tamura said Hylapharm approached him to collaborate on this project because of his expertise in lung cancer research.

"We have been collaborating since 2015 and already have one publication," Tamura said. "Lung cancer is the leading cause of cancer deaths with more than 200,000 new diagnoses made each year. We're hopeful the pulmonary delivery of aerosolized HylaPlat will be more efficacious and more tolerable than cisplatin delivered intravenously."

This method could prevent the spread of metastatic cancer, reduce the toxicity of chemotherapy and lessen the need for extensive surgical resection and radiotherapy, all of which cause irreversible harm to patients' health and quality of life, Tamura said.

The first phase of the project, titled "Aerosolized platinum nanoparticle chemotherapy for lung cancer," will position aerosolized HylaPlat for investigational new drug-enabling studies, after which Hylapharm will seek partnerships for phase one clinical trials with humans.

© Chemical Today Magazine


See the News in Chemical Today magazine

View the magazine on Mobile, download the Chemical Today magazine app



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Indian chemical industry to grow significantly by 2020

By Shivani Mody Presently, the Indian chemical industry is showing tremendous resilience in adverse global conditions. The exports are set to witness ...

Read more
Sawai to acquire Upsher-Smith's generic business for $1.1bn

TOKYO, JAPAN/ MINNEAPOLIS, US: Japan’s Sawai Pharmaceutical Co Ltd (Sawai) sign agreement to acquire generic pharmaceuticals business ...

Read more
VCI extends chemical logistics contract with Dachser

FRANKFURT, GERMANY: The German Chemical Industry Association (Verband der Chemischen Industrie e.V. or VCI) has extended its logistics contract with D ...

Read more
PM Modi's push for generic drugs to shift focus to chemists: IPA

NEW DELHI, INDIA: Patients may end up with drugs that "may not be effective at all" if doctors were made to prescribe only generic medicines as indica ...

Read more
WorleyParsons bags Biosynthetic Technologies' FEED contract in US

HOUSTON, US: WorleyParsons Limited (WOR) has been awarded a contract by Biosynthetic Technologies (BT) to perform front-end engineering design (FEED) ...

Read more
Anti-reflective coatings global analysis and opportunity 2017-2027

An anti-reflective coating is an optical coating that is applied on any lens surface or optical element to reduce the reflection. In a typical imaging ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X